Q-omics provides the consensus-scored SEC62 profile across patient tissues and cancer cell-line models. SEC62 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SEC62 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SEC62 protein abundance shows 27,226 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where SEC62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC62 survival associations across molecular data types. SEC62 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC62 RNA expression–survival associations across cancer types. High SEC62 expression shows unfavorable associations in BLCA, HNSC, UCEC, ACC and MESO, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SEC62 RNA expression.
This table summarizes SEC62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 13. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SEC62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC62 shows lower tumor expression in THCA, KICH, UCEC, KIRP and LUAD and higher tumor expression in HNSC. The HNSC box plot shows higher SEC62 RNA expression in tumor versus normal tissue (log2 FC = +0.877, t-test p < 0.001).
This table shows molecular features associated with SEC62 in patient tissues and cancer cell lines. In patient samples, SEC62 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
